These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27492836)

  • 1. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Sturkenboom MG; Akkerman OW; van Altena R; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JC
    Eur Respir J; 2016 Oct; 48(4):1237-1239. PubMed ID: 27492836
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
    Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
    Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
    Guiastrennec B; Ramachandran G; Karlsson MO; Kumar AKH; Bhavani PK; Gangadevi NP; Swaminathan S; Gupta A; Dooley KE; Savic RM
    Clin Pharmacol Ther; 2018 Oct; 104(4):733-741. PubMed ID: 29247506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.
    Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
    Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
    Motta I; Calcagno A; Bonora S
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):59-82. PubMed ID: 29226732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
    Deol P; Khuller GK; Joshi K
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
    De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
    Avachat AM; Bhise SB
    Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
    Egelund EF; Isaza R; Alsultan A; Peloquin CA
    J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
    Labana S; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
    Pienaar E; Dartois V; Linderman JJ; Kirschner DE
    BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.